Administrative/Regulatory
May 24, 2016
FTC settles with dietary supplement maker
The Federal Trade Commission announced a settlement Friday with Lunada Biomedical Inc. for using deceptive marketing and advertising for a supplement that purportedly treated menopause symptoms.
Daily Journal Staff Writer
The Federal Trade Commission announced a settlement Friday with Lunada Biomedical Inc. for using deceptive marketing and advertising about Amberen, a dietary supplement that purportedly treated a variety of menopause-related symptoms and caused weight loss in women over 40.
The Los Angeles-based company initially faced a $40 million judgment from U.S. District Judge Micha...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In